Renal allograft dysfunction associated with rifampin-tacrolimus interaction

Annals of Pharmacotherapy

Volumn 34, Issue 1, 2000, Pages 27-31

  Chenhsu, Rou Yee ^a   Loong, Che Chuan ^a   Chou, Mei Huei ^a   Lin, Ming Fang ^a   Yang, Wu Chang ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Renal transplantation; Rifampin; Tacrolimus

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RIFAMPICIN; TACROLIMUS;

ADULT; ARTICLE; CADAVER KIDNEY; CASE REPORT; CHINESE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0033984346     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19069     Document Type: Article

References (25)

1. Laskow DA, Neylan JF 3rd, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998;12:489-503.
2. Iwasaki K, Matsucla H, Nagase K, Shiraga T, Tokuma Y, Uchida K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Path Pharmacol 1993;82:209-16.
3. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effect of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:91-6.
4. Furlan V, Perello L, Jacquemin E, Debray D, Taburet AM. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995;59:1217-8.
5. Kiuchi T, Tanaka K, Inomata Y, Uemoto S, Satomura K, Egawa H, et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Transplant Proc 1996;28:3171-2.
6. Moreno M, Latorre A, Manzanares C, Morales E, Herrero JC, Dominguez-Gil B. Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant Proc 1999;31:2252-3.
7. Kahan BD. High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. Transplant Proc 1998;30:1639-41.
8. Brunet M, Pou L, Manzanares C, Palacios G, Corbella J. Multicenter comparison of first- and second-generation IMx tacrolimus microparticle enzyme immunoassays in liver and kidney transplantation. Ther Drug Monit 1998;20:676-9.
9. Prevalence of tuberculosis by sex and by surveys, Taiwan area 1957-1993. Health and vital statistics-I: General Health Statistics. Department of Health, the Executive Yuan, Republic of China, 1997:380.
10. Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM Jr, Lemann J Jr. Interaction of rifampin and glucocorticoids: adverse effect on renal allograft function. JAMA 1976;236:1958-60.
11. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72.
12. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52:453-7.
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
14. Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J. Heeman U, et al. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. Transplant Proc 1998; 30:1299-302.
15. Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998;65:248-52.
16. 1/2). Transplantation 1994;57:857-9.
17. Randhawa PS, Saad RS, Jordan M, Scantlebury V, Vivas C, Shapiro R. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vaculolization. Transplantation 1999; 67:85-9.
18. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.
19. Woodle ES, Cronin D, Newell KA, Millis JM, Bruce DS, Piper JB, et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation 1996;62:906-10.
20. Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 1996;42:1426-32.
21. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
22. 1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999;67:614-9.
23. Pascual M, Swinford RD, Ingelfinger JR, Williams WW, Cosimi AB, Tolkoff-Rubin N. Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol Today 1998;19:514-9.
24. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997;64: 1829-37.
25. Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, et al. Mycophenolate mofetil. Pharmacotherapy 1997;17:1178-97.